AngioDynamics, Inc. (NASDAQ:ANGO) had its Overweight rating reiterated by Canaccord Genuity with a $20.00 price target

ME Staff
-
0

Analyst Ratings For AngioDynamics, Inc. (NASDAQ:ANGO)

Today, Canaccord Genuity reiterated its Hold rating on AngioDynamics, Inc. (NASDAQ:ANGO) with a price target of $20.00.

There are 0 sell ratings, 5 hold ratings, 1 buy ratings, 0 strong buy ratings on the stock.

The current consensus rating on AngioDynamics, Inc. (NASDAQ:ANGO) is Hold with a consensus target price of $17.4433 per share, a potential 14.28% downside.

Some recent analyst ratings include

  • 7/12/2018-Canaccord Genuity Reiterated Rating of Hold.
  • 7/11/2018-Raymond James was Downgraded by analysts at Raymond James from a “Outperform ” rating to a ” Market Perform” rating. They now have a N/A price target on the stock.
  • 4/3/2018-UBS Group Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
  • 1/5/2018-Craig Hallum was Downgraded by analysts at Craig Hallum from a “Buy ” rating to a ” Hold” rating. They now have a N/A price target on the stock.
  • 9/29/2017-KeyCorp Reiterated Rating of Hold.

Recent Insider Trading Activity For AngioDynamics, Inc. (NASDAQ:ANGO)
AngioDynamics, Inc. (NASDAQ:ANGO) has insider ownership of 1.80% and institutional ownership of 98.38%.

  • On 7/24/2017 Jan Stern Reed, Director, bought 316 with an average share price of $16.00 per share and the total transaction amounting to $5,056.00.
  • On 7/21/2017 James C Clemmer, CEO, bought 5,000 with an average share price of $15.79 per share and the total transaction amounting to $78,950.00.
  • On 7/20/2017 James C Clemmer, CEO, bought 20,000 with an average share price of $15.64 per share and the total transaction amounting to $312,800.00.
  • On 4/12/2017 Avista Capital Partners Gp, Ll, Major Shareholder, sold 2,350,000 with an average share price of $16.00 per share and the total transaction amounting to $37,600,000.00.
  • On 8/5/2016 Avista Capital Partners Gp, Ll, Major Shareholder, sold 2,241,000 with an average share price of $14.62 per share and the total transaction amounting to $32,763,420.00.
  • On 8/5/2016 David F Burgstahler, Director, sold 2,250,000 with an average share price of $14.62 per share and the total transaction amounting to $32,895,000.00.
  • On 5/6/2016 Charles R Greiner, VP, sold 3,508 with an average share price of $12.31 per share and the total transaction amounting to $43,183.48.

About AngioDynamics, Inc. (NASDAQ:ANGO)
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

Recent Trading Activity for AngioDynamics, Inc. (NASDAQ:ANGO)
Shares of AngioDynamics, Inc. closed the previous trading session at 20.43 up +1.48 7.84% with 19.06 shares trading hands.